

# Jaclyn Frances Hechtman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8447373/publications.pdf>

Version: 2024-02-01

86  
papers

10,178  
citations

101384

36  
h-index

54797

84  
g-index

87  
all docs

87  
docs citations

87  
times ranked

16427  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
2	Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). <i>Journal of Molecular Diagnostics</i> , 2015, 17, 251-264.	1.2	1,566
3	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018, 33, 125-136.e3.	7.7	589
4	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 471.	3.4	426
5	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019, 364, 485-491.	6.0	395
6	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 2116-2126.	3.2	390
7	NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. <i>Modern Pathology</i> , 2020, 33, 38-46.	2.9	373
8	Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1547-1551.	2.1	353
9	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. <i>Cancer Discovery</i> , 2018, 8, 49-58.	7.7	275
10	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 821-831.	5.1	243
11	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal/Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
12	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 967-976.	3.2	164
13	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. <i>Modern Pathology</i> , 2016, 29, 1433-1442.	2.9	144
14	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. <i>Nature Medicine</i> , 2019, 25, 1422-1427.	15.2	144
15	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2351-2358.	3.2	141
16	Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. <i>Cancer Research</i> , 2019, 79, 3163-3168.	0.4	138
17	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019, 9, 199-209.	7.7	115
18	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. <i>Cancer Research</i> , 2019, 79, 1047-1053.	0.4	112

#	ARTICLE	IF	CITATIONS
19	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. <i>Clinical Cancer Research</i> , 2020, 26, 1624-1632.	3.2	103
20	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 244-254.	1.2	96
21	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusionâ€œPositive Lung Cancer by Combining Selpercatinib with Crizotinib. <i>Clinical Cancer Research</i> , 2021, 27, 34-42.	3.2	87
22	HER2/neu Gene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Histopathology, Diagnostic Testing, and Clinical Implications. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 691-697.	1.2	82
23	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphologyâ€œmolecular associations: clinical and biological implications. <i>Modern Pathology</i> , 2017, 30, 599-609.	2.9	74
24	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6160-6169.	3.2	73
25	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2021, 74, 1429-1444.	3.6	73
26	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	5.8	68
27	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. <i>Cancer Research</i> , 2017, 77, 6513-6523.	0.4	58
28	Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. <i>Modern Pathology</i> , 2020, 33, 871-879.	2.9	58
29	Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. <i>Clinical Cancer Research</i> , 2017, 23, 4753-4760.	3.2	56
30	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. <i>Nature Communications</i> , 2017, 8, 14674.	5.8	53
31	Lineage Reversion Drives WNT Independence in Intestinal Cancer. <i>Cancer Discovery</i> , 2020, 10, 1590-1609.	7.7	52
32	Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). <i>Modern Pathology</i> , 2015, 28, 1123-1129.	2.9	51
33	Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature. <i>Annals of Surgical Oncology</i> , 2015, 22, 2633-2639.	0.7	46
34	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. <i>Molecular Cancer Research</i> , 2016, 14, 296-301.	1.5	46
35	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. <i>Journal of Clinical Investigation</i> , 2018, 128, 3819-3825.	3.9	45
36	Clinical and genetic determinants of ovarian metastases from colorectal cancer. <i>Cancer</i> , 2017, 123, 1134-1143.	2.0	43

#	ARTICLE	IF	CITATIONS
37	A Performance Comparison of Commonly Used Assays to Detect RET Fusions. <i>Clinical Cancer Research</i> , 2021, 27, 1316-1328.	3.2	39
38	Hepatocellular Carcinoma Arising in a Pigmented Telangiectatic Adenoma With Nuclear $\beta$ -catenin and Glutamine Synthetase Positivity. <i>American Journal of Surgical Pathology</i> , 2011, 35, 927-932.	2.1	37
39	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. <i>Cancer Discovery</i> , 2021, 11, 126-141.	7.7	34
40	Germline <i>SDHA</i> mutations in children and adults with cancer. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002584.	0.5	33
41	Carcinomas assemble a filamentous CXCL12 keratin-19 coating that suppresses T cell-mediated immune attack. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	32
42	Novel oncogene and tumor suppressor mutations in <i>KIT</i> and <i>PDGFRA</i> wild type gastrointestinal stromal tumors revealed by next generation sequencing. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 177-184.	1.5	28
43	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019, 32, 110-121.	2.9	28
44	V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. <i>Cancer Discovery</i> , 2019, 9, 1182-1191.	7.7	27
45	Recurrent, truncating <i>SOX9</i> mutations are associated with <i>SOX9</i> overexpression, <i>KRAS</i> mutation, and <i>TP53</i> wild type status in colorectal carcinoma. <i>Oncotarget</i> , 2016, 7, 50875-50882.	0.8	26
46	Reliable Clinical MLH1 Promoter Hypermethylation Assessment Using a High-Throughput Genome-Wide Methylation Array Platform. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 368-375.	1.2	25
47	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. <i>Molecular Cancer Research</i> , 2017, 15, 708-713.	1.5	24
48	Carcinoma Ex Microcystic Adenoma of the Pancreas. <i>American Journal of Surgical Pathology</i> , 2012, 36, 305-310.	2.1	23
49	Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1429-1437.	3.2	23
50	Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study. <i>Human Pathology</i> , 2013, 44, 1400-1405.	1.1	21
51	FOLFICIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e39-e52.	1.0	21
52	AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. <i>Molecular Cancer Research</i> , 2015, 13, 1003-1008.	1.5	20
53	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2027-2033.	0.7	19
54	ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance. <i>Human Pathology</i> , 2016, 53, 97-104.	1.1	18

#	ARTICLE	IF	CITATIONS
55	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. <i>Familial Cancer</i> , 2017, 16, 525-529.	0.9	18
56	Current Management of Appendiceal Neoplasms. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 118-132.	1.8	18
57	Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. <i>Human Pathology</i> , 2017, 62, 74-82.	1.1	17
58	Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations. <i>Familial Cancer</i> , 2018, 17, 225-228.	0.9	17
59	Neurogenic Polyps of the Gastrointestinal Tract: A Clinicopathologic Review With Emphasis on Differential Diagnosis and Syndromic Associations. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 133-139.	1.2	16
60	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114753.	2.8	15
61	Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA. <i>Human Pathology</i> , 2019, 83, 1-6.	1.1	14
62	EBV-associated lymphoepithelioma-like carcinoma of the pancreas: Case report with targeted sequencing analysis. <i>Pancreatology</i> , 2015, 15, 302-304.	0.5	13
63	Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants. <i>Human Pathology</i> , 2020, 106, 45-53.	1.1	13
64	Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. <i>Modern Pathology</i> , 2019, 32, 1551-1562.	2.9	12
65	EGFR Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1561-1569.	3.0	12
66	Ischemic bowel due to embolization from an isolated mobile thrombus of the ascending aorta: a case report and review of the literature. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 238-241.	1.0	10
67	Efficacy of Combined VEGFR1-3, PDGF $\alpha$ / $\beta$ , and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3811-3817.	3.2	10
68	Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. <i>Oncologist</i> , 2020, 25, e68-e74.	1.9	10
69	Pan-Cancer Biomarkers: Changing the Landscape of Molecular Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 692-698.	1.2	10
70	Genomic stratification beyond Ras/Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. <i>Cancer Medicine</i> , 2019, 8, 6538-6548.	1.3	8
71	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. <i>Familial Cancer</i> , 2020, 20, 201-213.	0.9	8
72	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. <i>Clinical Cancer Research</i> , 2021, 27, 3491-3498.	3.2	8

#	ARTICLE	IF	CITATIONS
73	Thymomas diagnosed during pregnancy: two cases in young women without paraneoplastic or autoimmune disease. <i>Annals of Diagnostic Pathology</i> , 2012, 16, 392-396.	0.6	7
74	Intraductal Polypoid Lipid-Rich Neuroendocrine Tumor of the Pancreas with Entrapped Ductules: Case Report and Review of the Literature. <i>Endocrine Pathology</i> , 2013, 24, 30-35.	5.2	5
75	Intramuscular corpora amylacea adjacent to ileal low-grade neuroendocrine tumours (typical) Tj ETQq1 1 0.784314 rgBT /Overlock 10 <i>Pathology</i> , 2013, 66, 569-572.	1.0	5
76	Multiple Endocrine Neoplasia Type 1 Associated With a New Mutation in the Menin Gene and a Midgut Neuroendocrine Tumor. <i>Pancreas</i> , 2014, 43, 145-146.	0.5	5
77	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts. <i>JCO Precision Oncology</i> , 2022, 6, e2100242.	1.5	5
78	Anti-Glutamate Receptor 2 as a New Potential Diagnostic Probe for Prostatic Adenocarcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2012, 20, 344-349.	0.6	4
79	Mycobacterial pseudotumor of the plantar fascia: how common is it?. <i>Clinical Imaging</i> , 2013, 37, 802-805.	0.8	4
80	Subclinical focal cholangitis mimicking liver metastasis in asymptomatic patients with history of pancreatic ductal adenocarcinoma and biliary tree intervention. <i>Cancer Imaging</i> , 2017, 17, 21.	1.2	4
81	Corpora amylacea in gastrointestinal leiomyomas: a clinical, light microscopic, ultrastructural and immunohistochemical study with comparison to hyaline globules. <i>Journal of Clinical Pathology</i> , 2013, 66, 951-955.	1.0	3
82	The past, present, and future of HER2 ( <i>ERBB2</i> ) in cancer: Approaches to molecular testing and an evolving role in targeted therapy. <i>Cancer Cytopathology</i> , 2019, 127, 428-431.	1.4	1
83	Reply to Singh et al.. <i>Modern Pathology</i> , 2021, 34, 1033-1034.	2.9	1
84	Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100365.	1.5	1
85	Hepatic Mass in a 73-Year-Old Man. <i>Gastroenterology</i> , 2012, 142, 434-679.	0.6	0
86	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. <i>Blood</i> , 2017, 130, 794-794.	0.6	0